To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
Status:
Recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate 24-week efficacy and 52 week immunogenicity of subcutaneous Eporon
versus Epoetin Alfa (Eprex) in the treatment of anemia associated with chronic renal failure
in pre-dialysis patients. A total of 214 patients will be enrolled in Turkey.